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Abstract The objective of this study was to document
persistent pulmonary symptoms and pulmonary function
abnormalities in adults surviving hantavirus pulmonary
syndrome (HPS). Acute infection by most hantaviruses
result in mortality rates of 25–35%, while in Panama the
mortality rate of 10% is contrasted by an unusually high
incidence. In all types of HPS, the viral prodrome, car-
diopulmonary phase due to massive pulmonary capillary
leak syndrome, and spontaneous diuresis are followed by a
convalescent phase with exertional dyspnea for 3–4 weeks,
but the frequency of persistent symptoms is not known.
In this observational study of a convenience sample, 14
survivors of HPS caused by Choclo virus infection in
Panama and 9 survivors of HPS caused by Sin Nombre
virus infection in New Mexico completed a questionnaire
and pulmonary function tests up to 8 years after infection.
In both groups, exertional dyspnea persisted for 1–2 years
after acute infection in 43% (Panama) and 77% (New
Mexico) of survivors surveyed. Reduction in midexpiratory
ﬂows (FEF25–75%), increased residual volume (RV), and
reduced diffusion capacity (DLCO/VA) also were common
in both populations; but the severity of reduced expiratory
ﬂow did not correlate with exertional dyspnea. Symptoms
referable to previous hantavirus infection had resolved
within 3 years of acute infection in most but not all patients
in the Panama group. Temporary exertional dyspnea and
reduced expiratory ﬂow are common in early convales-
cence after HPS but resolves in almost all patients.
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Abbreviations
DLCO Diffusing capacity of the lung for carbon
monoxide
DLCO/VA Diffusion capacity/volume alveolar
EIA Enzyme-linked immunoassay
ECMO Extracorporeal membrane oxygenation
FEF Forced expiratory ﬂow
FEV1/FVC Forced expiratory volume in 1 s/forced vital
capacity ratio
HPS Hantavirus pulmonary syndrome
MV Mechanical ventilation
RT–PCR Reverse transcriptase-polymerase chain
reaction
RV Residual volume
SN Sin Nombre virus
TLC Total lung capacity
Introduction
Since its ﬁrst discovery in the American Southwest in
1993, hantavirus pulmonary syndrome (HPS) has been
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is due to acute self-limited infection by a variety of
hantaviruses hosted by wild sigmodontine rodents [1].
More than 400 individuals with HPS in North America and
more than 2000 in South America have experienced mor-
tality rates of 25–35%. Pulmonary capillary endothelial
cells express higher densities of infection [2] compared
with other organs associated with a pneumonitis charac-
terized by mononuclear cell inﬁltration and pulmonary
edema [3]. The clinical disease is manifested by a viral
prodrome of 1–8 days, followed by the precipitous onset of
pulmonary edema with or without cardiogenic shock [4–6].
The cardiopulmonary phase persists for up to 1 week,
followed by spontaneous diuresis and a convalescent phase
characterized by weakness and exertional dyspnea for
3–4 weeks in almost all survivors.
Some survivors of HPS in New Mexico reported exer-
tional dyspnea and other symptoms persisting for longer
than 6 months. Similar residual symptoms were commonly
noted also in Panama, where Choclo virus infection is
associated with a lower mortality rate of 16% among
hospitalized patients with HPS [7]. Infection with Choclo
virus frequently results in mild infection without pulmon-
ary complications, and seroprevalence rates over 20% are
common in the adult population without a history of hos-
pitalization for HPS [8]. This report documents exertional
dyspnea and decreased expiratory ﬂow rates in late con-
valescence among small groups of patients in Panama
infected in 2000 and in New Mexico infected in 1993–
1995.
Materials and Methods
Acute HPS Adults—New Mexico
In 1993 through 1994 in New Mexico, 23 adults were
diagnosed with HPS by immunoblot serology and reverse
transcriptase-polymerase chain reaction (RT–PCR) [9].
Nine patients (average age = 35 years) returned for rou-
tine follow-up exam 2–14 months after admission. Patients
self-reporting respiratory symptoms not present before
acute hantavirus infection underwent a brief structured
questionnaire and pulmonary function testing. Three and
8 years after acute infection, the patients were contacted by
phone to repeat the questionnaire but spirometry was not
obtained. None were active smokers and one woman had
quit smoking 16 years earlier after a 10-pack-year history.
None had underlying chronic disease, and all were
employed before the acute hantavirus infection. Five of the
nine required mechanical ventilation, and one received
extracorporeal membrane oxygenation (ECMO) treatment.
Acute HPS Adults—Panama
In 2000 in Panama, 22 adults and 1 adolescent were
diagnosed by serology with HPS which was conﬁrmed as
Choclo infection by RT–PCR of RNA extracted from an
acute blood specimen. Five of these patients died within
48 h of diagnosis and four were lost to follow-up. The 14
remaining patients consented to be interviewed by two of
the authors (FG and FK) for residual pulmonary symp-
toms using the same questionnaire 10–14 months after
hospitalization for HPS. Interviewed subjects included 8
women and 6 men aged 27–56 years (mean = 38 years).
Pulmonary function tests were requested and obtained on
11 of the 14 subjects. Interviews were conducted with the
same questionnaire 2 and 8 years later from 11 and 5 of
the 14 patients, respectively, and pulmonary function tests
were repeated when considered clinically appropriate by
the attending physician. All subjects were employed and
active previous to hantavirus infection; none were active
smokers and one male had quit smoking 10 years prior to
infection. One patient in each of the 2- and 8-year-follow-
up groups had essential hypertension, depression, chronic
back pain, and a history of drug abuse, but none were ever
diagnosed or treated for an acute or chronic respiratory
disease. Five had HPS requiring mechanical ventilation
(MV); two of the ﬁve also required intravenous ﬂuids for
hypotension. Nine required oxygenation using only nasal
cannula or mask.
Hantavirus-Seropositive Adults—Panama
In 2000, the Ministry of Health in Panama conducted
serosurveys of household and neighborhood contacts of
the above-mentioned HPS patients. Among the 48 people
surveyed, 5 adults were seropositive for hantavirus-spe-
ciﬁc serum IgG antibody as detected by both strip
immunoblot and EIA assays. Speciﬁcity for previous
Choclo virus infection was conﬁrmed by focus assay that
neutralizes Choclo virus in Vero E6 cells in a titer
greater than 1:200 (Koster, unpublished data). These
contacts reported no previous hospitalization or treatment
for an acute severe respiratory illness, none had under-
lying disease, and none reported a history of smoking
cigarettes. Ten to 16 months after HPS in the family
member, the contacts were interviewed once by ques-
tionnaire and spirometry was performed. The clinical
protocols and informed consent were approved by the
Ministry of Health of Panama, the University of New
Mexico Human Research Review Committee, and the
ICIDR Review Committee of the National Institute of
Allergy and Infectious Diseases.
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The symptom survey instrument of 20 open-ended ques-
tions was designed for this study to elicit self-reported
symptoms and included 7 questions on respiratory com-
plaints, 8 on nonrespiratory functions including sleep, and
5 on general health. New medical diagnoses were sought,
as well as recent and remote history of smoking, alcohol
use, and recreational drug use. The degree of respiratory
difﬁculty that was new since the diagnosis of hantavirus
infection was graded as 4? if dyspnea prevented sedentary
occupation, 3? if the subject was unable to walk more than
50 m on level ground, 2? if the subject was unable to
climb a ﬂight of stairs or a hill more than 10 m in height,
and 1? if the subject was unable to engage in physical
sport requiring running or jumping but was unaffected by
normal daily activity. Although the questions were the
same for each population, use of English and Spanish
prevented meaningful internal validation.
Spirometry
Pulmonary function testing in Panama and in the United
States was performed by a computerized wedge spirometer
to obtain lung volumes, inspiratory and expiratory ﬂow
rates, and carbon monoxide diffusion capacity (DLCO).
Standardization of spirometry was achieved by using ATS
criteria [10] and a minimum of four forced expiratory
efforts and inspection of the ﬂow volume loop to ensure
best effort results. Results were compared to normal mid-
dle-aged North American adults [11].
Results
Symptoms
Six of the 14 (43%) Panamanian subjects reported exer-
tional dyspnea, graded as 3? in two patients, 2? in two
patients, and 1? in two patients, persisting for 1 year after
acute infection. The four subjects reporting grade 2? and
3? dyspnea also reported sleep disturbance with nocturnal
dry cough and fatigue on rising in the morning. No subject
reported wheezing, orthopnea, daytime cough, or sputum
production. Three of the six dyspneic subjects had been
treated by MV during acute HPS, compared to two of eight
subjects without dyspnea (not signiﬁcant by Fisher’s exact
test). The ﬁve seropositive neighborhood contacts studied
by questionnaire and spirometry reported no respiratory
symptoms, including exertional dyspnea. Among the nine
New Mexican subjects surveyed 10–14 months after
admission for acute HPS, seven (77%) reported exertional
dyspnea manifested as either difﬁculty in engaging in
hiking or bicycling (grade 1? in three subjects) or difﬁ-
culty climbing stairs (grade 2? in four subjects). Two
subjects reported fatigue on rising in the morning, but none
reported sleep disturbance or nocturnal cough.
When interviewed 3 years after acute hantavirus infec-
tion in Panama, only two of six subjects reported dyspnea
when climbing stairs (grade 2?). A third man reported
continued exertional dyspnea; spirometry identiﬁed severe
restrictive lung disease consistent with his history of crack
inhalation. One woman had developed disseminated
malignant melanoma and new exertional dyspnea with
cachexia. When interviewed 8 years after HPS, four indi-
viduals reported exertional dyspnea (grade 2?), and two of
these also reported sleep interruption due to nocturnal
cough. The four seropositive household contacts in Panama
continued to report no respiratory symptoms. Among nine
New Mexican subjects, only one reported increased exer-
tional dyspnea at 3 and 8 years after acute infection.
Pulmonary Function
In 11 Panamanian survivors tested 1 year after HPS, the
FEV1/FVC ratio was a mean of 103 (range = 0.61–1.31).
The one individual below 98% predicted (ratio = 0.61)
was the active smoker. The average FEV1/FVC ratio of the
seropositive controls was 0.98 (range = 0.88–1.08). In
New Mexican survivors 6–12 months after HPS, the
average FVC was 102% predicted (range = 88–115%) and
the average FEV1 was 97% predicted (range = 84–111%).
These convalescence values contrasted with the previous
discharge values in three survivors measured (FVC mean
= 74% predicted, range = 67–76%; FEV1 mean = 70%,
range = 62–73%). In contrast, FEF25–75% values were
modestly to markedly reduced in most subjects of both
populations (Fig. 1). Among the six dyspneic Panamani-
ans, four of ﬁve studied had abnormal FEF25–75%,
mean = 63% predicted (range = 55–93%). Six of the
eight subjects without exertional dyspnea were tested and
four had signiﬁcantly reduced FEF25–75% values, with a
mean of 60.7% predicted. There was no relationship
between exertional dyspnea and abnormal expiratory ﬂow
rates (not signiﬁcant by Mann–Whitney rank sum test).
Among the ﬁve asymptomatic seropositive contacts, the
four without asthma had a mean FEF25–75% of 82% pre-
dicted (range = 59–102%).
Residual volume/total lung capacity ratio (RV/TLC)
was increased in most New Mexican survivors tested
at discharge (mean = 148% of expected, N = 3) but
appeared to improve in three subjects (mean = 101%) by
2–10 months later (Fig. 1). Only two Panamanian survi-
vors had increased RV when tested 1 year after discharge.
Among the New Mexican survivors, four of seven had
diminished DLCO at discharge, but these values improved
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Panamanian survivor had normal DLCO at testing 1 year
after discharge (Fig. 1). There was no apparent relationship
in these small groups between DLCO/VA values and prior
MV or persistent symptoms of exertional dyspnea.
Discussion
This preliminary descriptive study was initiated to assess
the prevalence of persistent dyspnea after hantavirus
infection in Panama and the U.S. Southwest. Results indi-
cate that while exertional dyspnea and expiratory ﬂow
abnormalities may commonly persist for up to 1 year, the
residual clinical effects of hantavirus lung infection appear
to resolve in most individuals among the Panamanian and
North American groups studied 3 and 8 years after acute
infection. While HPS is caused by different hantaviruses in
the two regions, the pattern of persistent pulmonary func-
tion abnormalities, expiratory ﬂow reduction, and increased
residual volume was similar in both groups, likely due to the
common pathogenetic features of HPS seen throughout the
Americas. The persistence of respiratory symptoms was not
correlated with either the severity of acute disease or the use
of MV. Furthermore, in this small study respiratory symp-
toms did not correlate with persistent respiratory dysfunc-
tion detected by simple spirometry. Reduced gas transport
capacity of the lung is not predictive of exertional dyspnea
in survivors of Legionella pneumonia [12]. Moreover, dis-
cordance between respiratory symptoms and evidence for
small-airway ﬂow impairment is found among middle-aged
nonsmoking Americans without a history of severe respi-
ratory infection [13].
The possible mechanism of exertional dyspnea and
persistent small-airway airﬂow obstruction resulting from
hantavirus pneumonitis is not known. Acute respiratory
distress syndrome is associated with decreased DLCO but
with normal lung volumes [14]. Acute inﬂuenza A induced
gas transport abnormality in the lung for up to 6 months in
healthy adults, although resolution was documented in all
survivors [15]. Small-airway ﬂow also was temporarily
reduced in acute inﬂuenza, while other spirometric mea-
sures of pulmonary function were unaffected [16]. Caution
should be taken in making direct comparisons between
hantavirus pneumonitis and other viral pneumonitides
because, unlike the infected epithelial cells seen in inﬂu-
enza pneumonitis, acute hantavirus pneumonitis is char-
acterized by an intense viral infection of pulmonary
capillary endothelial cells [2].
Measures of neuropsychological health were not sought
in this preliminary survey, although disruption of sleep was
commonly reported during the ﬁrst year of convalescence.
Survivors of severe acute lung injury perceived a decline in
general physical health [17], and post-traumatic stress
disorder may be induced by acute Legionella pneumonia
[18]. Three HPS survivors in Panama reported persistent
general health impairment attributable to Choclo virus
infection 8 years later, but a larger study with controls is
required to distinguish HPS from other causes. Recovery
from HPS due to SN virus may lead to general health
impairment [19] or renal dysfunction years after infection
[20].
This small study does not rule out the persistence of
disability for years after acute infection in a small number
of survivors, nor does it rule out the persistence of lung
structural injury that may synergize with other lung insults
such as ventilator-induced lung injury to induce chronic
respiratory disability in this population. Our study is lim-
ited by the small patient population, the lack of ambulatory
pulse oximetry, and pulmonary function testing at the time
Fig. 1 Pulmonary function testing in late convalescence in 9 adult
survivors of Sin Nombre virus infection in New Mexico tested at
hospital discharge and/or 3–6 months later, and in 14 adult survivors
of Choclo virus infection in Panama tested 10–14 months after
hospital discharge. Left panel FEF25–75% as % predicted for gender,
age, and weight. Middle panel RV/TLC ratio as % predicted for
gender, age, and weight. Right panel DLCO/VA as % predicted.
Group A: 9 subjects studied within 1 month after discharge with HPS
due to Sin Nombre virus infection in New Mexico. Group B: 3 of the
9 subjects studied 3–6 months later. Group C: 14 subjects studied 10–
14 months after HPS due to Choclo virus infection in Panama. Group
D: 4 subjects seropositive for previous hantavirus infection in Panama
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123of symptom resolution. Nonetheless, it is unlikely that
hantavirus infection contributes signiﬁcantly to the preva-
lence of chronic respiratory dysfunction in either country.
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